Results 41 to 50 of about 3,240,291 (296)

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus

Сахарный диабет, 2012
В Москве 11 апреля 2012 г. состоялость заседание экспертного совета по применению нового ингибитора дипептидилпептидазы-4 (ДПП-4) ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типа (СД2).
Editorial team Diabetes Mellitus
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

Diabetic Mononeuropathies and Diabetic Amyotrophy

Diabetes Therapy, 2022
This brief review describes the etiology, pathophysiology, clinical features, therapy and prognosis of the diabetic mononeuropathies and diabetic amyotrophy and neuropathic cachexia. Mononeuropathies include cranial neuropathies, of which the oculomotor nerve is most commonly affected, and are thought to be due to microvascular occlusion. Peripherally,
openaire   +2 more sources

Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21 [PDF]

, 2009
OBJECTIVE—Fibroblast growth factor (FGF)-21 improves insulin sensitivity and lipid metabolism in obese or diabetic animal models, while human studies revealed increased FGF-21 levels in obesity and type 2 diabetes.
Pfeiffer, Andreas F. H., Meinus, S., Andres, Janin, Biedasek, Katrin, Biedasek, K., Spranger, J., Mai, K., Reinecke, F., Spuler, S., Pfeiffer, A.F., Moehlig, M., Sabath, Markus, Clemenz, M., Mai, Knut, Bobbert, T., Meinus, Sabine, Spranger, Joachim, Reinecke, Franziska, Weickert, Martin O., Bobbert, Thomas, Weicht, J., Möhlig, Matthias, Andres, J., Weicht, Jessica, Kintscher, U., Spuler, Simone, Clemenz, Markus, Sabath, M., Weickert, M.O., Kintscher, Ulrich   +29 more
core   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues

Сахарный диабет, 2016
The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects ...
Editorial team Diabetes Mellitus
doaj   +1 more source

Smaller is better: nanobodies meet NMR

FEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Preconception counselling in women with diabetes: a population-based study in the North of England [PDF]

, 2009
To investigate the association of preconception counseling with markers of care and maternal characteristics in women with pregestational diabetes. The study includes data from a regional multi-center survey on 588 women with pregestational diabetes who ...
Chandler, Colin, Bell, Ruth, Tripathi, Anvish, Aarvold, Joan, Chandler, Colin; id_orcid, Rankin, Judith, Tripathi, Avnish   +6 more
core   +1 more source